A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

This Phase 2 study tests a combination of two targeted cancer drugs — ABSK043 and firmonertinib — for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation and expresses a protein called PD-L1. The study includes both patients who have already tried EGFR-targeted therapy and those who haven't. **You may be eligible if...** - You have advanced or metastatic non-small cell lung cancer - Your tumor has an EGFR mutation (exon 19 deletion or L858R) - Your tumor tests positive for PD-L1 (≥1%) - You have measurable tumors on scans - Your blood and organ function are within acceptable limits **You may NOT be eligible if...** - Your lung cancer is predominantly squamous cell type, or contains small cell or neuroendocrine components - You have had or currently have interstitial lung disease or serious lung inflammation - You have active or symptomatic brain metastases - You have unresolved significant side effects from prior treatment - You are on high-dose steroids or immunosuppressants Talk to your doctor to see if this trial is right for you.